
Eikon secures $350.7 million to advance oncology programmes
Eikon Therapeutics has announced the initial closing of a $350.7 million Series D financing, led by existing investors. Since its founding in 2019, the company has privately raised over $1.1 billion. “Eikon has made remarkable progress in advancing a pivotal-stage clinical pipeline and early-stage development programme… Read More
